| Hepatocellular Carcinoma |
1 |
1 |
| Biologic Therapy |
0 |
0.93 |
| Cancer |
0 |
0.56 |
| Immunotherapy |
0 |
0.99 |
| Liver |
0 |
0.56 |
| Toxicology |
0 |
0.39 |
| Vascular Endothelial Growth Factor |
0 |
0.28 |
| Angiogenesis Inhibitors |
0 |
0.21 |
| Humanized Monoclonal Antibody |
0 |
0.21 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Portal Vein Thrombosis |
0 |
0.12 |
| Thromboembolism |
0 |
0.1 |
| Hepatitis C Virus |
0 |
0.09 |
| Attending Physician |
0 |
0.07 |
| Biomarker |
0 |
0.07 |
| California |
0 |
0.07 |
| Hepatitis |
0 |
0.07 |
| New York |
0 |
0.07 |
| Orphan Drugs |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Steroids |
0 |
0.07 |
| Thrombosis |
0 |
0.07 |
| Tumor |
0 |
0.07 |
| Vein |
0 |
0.07 |